Table 2 Summary of recent pivotal clinical trials in advanced soft tissue sarcomas
From: Spotlight on landmark oncology trials: the latest evidence and novel trial designs
Tumour type, phase [reference] | Line of therapy | Arms (experimental vs. control) | Response rate | Clinical benefit rate | Median PFS (months, P value) | Median OS (months, P value) |
|---|---|---|---|---|---|---|
Non-adipocytic soft tissue sarcoma, phase 3, n = 369 [19] | Second or later (after anthracycline) | Pazopanib 800 mg/m2 vs. placebo | 6% vs. 0% | 73% vs. 38% | 4.6 vs. 1.6 (P < 0.0001) | 12.5 vs. 10.7 (P = 0.25) |
Liposarcoma and leiomyosarcoma, phase 3, n = 518 [20] | Second or later (after anthracycline) | Trabectedine 1.5 mg/m2 vs. dacarbazine 1000 mg/m2 | 10% vs. 7% | 61% vs. 42% | 4.2 vs. 1.5 (P < 0.001) | 12.4 vs. 12.9 (P = 0.37) |
Liposarcoma and leiomyosarcoma, phase 3, n = 452 [21] | Third or later (after anthracycline) | Eribulin mesylate 1.4 mg/m2 vs. dacarbazine 850–1200 mg/m2 | 5% vs. 4% | 57% vs. 52% | 2.6 vs. 2.6 (P = 0.23) | 13.5 vs. 11.5 (P = 0.01) |
Soft tissue sarcoma, phase 2, n = 133 [22] | First line | Olaratumab 15 mg/kg plus doxorubicin 75 mg/m2 vs. doxorubicin alone 75 mg/m2 | 18.2% vs. 11.9% | 77.3% vs. 62.7% | 6.6 vs. 4.1 (P = 0.06) | 26.5 vs. 14.7 (P = 0.0003) |